Newsletter Tool

Today’s Big News

Dec 9, 2024

AbbVie's Parkinson's prospect hits again in phase 3, completing clean sweep to tee up FDA filing

Carisma axes sole clinical cell therapy candidate, lays off 23 workers

BioAge's phase 2 obesity study derailed by liver side effects 2 months after IPO

Enanta's RSV antiviral reduces viral load in phase 2 pediatric study

Vivoryon's Alzheimer's asset suffers 2nd phase 2 fail, but hope as kidney drug remains

The 2nd Dimension: VC raises $500M fund for entrepreneurs pioneering life sci, tech

Merck ADC RORs into phase 3 with 100% complete response rate

Featured

AbbVie's Parkinson's prospect hits again in phase 3, completing clean sweep to tee up FDA filing

By Nick Paul Taylor

AbbVie has completed a hat trick of phase 3 wins for its Parkinson’s disease prospect tavapadon, teeing the drugmaker up to file for FDA approval of drug candidate in 2025.

Carisma axes sole clinical cell therapy candidate, lays off 23 workers

By Gabrielle Masson

For the second time this year, Carisma is laying off staff. The newly announced restructure includes several company leaders hitting the exit and the discontinuation of the biotech’s sole clinical candidate.

BioAge's phase 2 obesity study derailed by liver side effects 2 months after IPO

By James Waldron

It didn’t take long for the shine to come off one of biotech’s recent IPO success stories, with BioAge Labs scrapping its phase 2-stage obesity prospect barely two months after going public.

What’s next in AI’s drug discovery journey

Enanta's RSV antiviral reduces viral load in phase 2 pediatric study

By James Waldron

Enanta Pharmaceuticals’ respiratory syncytial virus antiviral reduced the viral load in a phase 2 study in children, maintaining hopes the biotech can find a niche in a market now dominated by Big Pharma.

Vivoryon's Alzheimer's asset suffers 2nd phase 2 fail, but hope as kidney drug remains

By James Waldron

Vivoryon Therapeutics’ glutaminyl cyclase inhibitor has failed a second phase 2 Alzheimer’s disease study this year, leaving the German biotech to try to find a silver lining in the drug’s potential to improve kidney function.

The 2nd Dimension: VC raises $500M fund for entrepreneurs pioneering life sci, tech

By Gabrielle Masson

VC Dimension has closed a $500 million fund for entrepreneurs that are “pioneering at the vanguard of life sciences and technology."

Merck ADC RORs into phase 3 with 100% complete response rate

By Nick Paul Taylor

Merck & Co. has shown off data on its ROR1-directed antibody-drug conjugate, trumpeting a 100% complete response rate but also reporting safety signals that informed the decision to take the low dose into phase 3.

ASH: AstraZeneca proposes fixed-duration Calquence combos in chronic lymphocytic leukemia

By Angus Liu

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has positive data suggesting two fixed-duration combinations containing its Calquence can work in newly diagnosed chronic lymphocytic leukemia.

Merck gets rare win with Keytruda-Lynparza combo but role of Keytruda in ovarian cancer 'remains uncertain'

By Kevin Dunleavy

Merck hasn’t had much luck pairing cancer superstar Keytruda with PARP inhibitor Lynparza. But after flunking three clinical trials with the combination, the company has emerged with a tepid win with the pairing hitting the primary endpoint in an ovarian cancer study.

Fierce podcasts

Don’t miss an episode

What can we learn from 2024’s biotech IPOs?

This week on "The Top Line," we explore the biotech IPO market rebound and ask: Is the momentum here to stay?

NCQA: Best practices for measuring health inequities

Meet 2024’s fiercest women in life sciences

Resources

Whitepaper

Building a “Best Practice” R&D Organization in Biopharma

We interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Single Cell RNA Profiling FFPE Tissue

Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence.

Straight to Market in an Autoinjector

The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors.

Presented by Lonza

Whitepaper

Planning for success in cell-based manufacturing

Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes.

Presented by: Thermo Fisher Scientific